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Case Synopsis 
We report a 61-year-old woman with a 30-year 
history of severe psoriasis and several admissions to 
the hospital because of erythrodermic flares. Her 
past medical history included obesity, insulin-
dependent diabetes mellitus, and liver cirrhosis 
related to alcoholic and non-alcoholic fatty liver 
diseases (Child Pugh class A). Through the years, 
multiple therapies were attempted including 
cyclosporine (stopped due to nephrotoxicity), 
narrowband UVB (NB-UVB) phototherapy (non-
responder), etanercept (primary non-responder), 
ustekinumab (secondary non-responder), and 
adalimumab (primary non-responder). Given the 
lack of response to previous treatments, the patient 
started treatment with secukinumab 300mg as per 
label. After 8 weeks, a PASI50-75 response was 
achieved. However, after week 12, the patient started 
to lose response with reappearance of plaque-type 
psoriasis (absolute PASI=18). Secukinumab was 
increased to 300mg every other week and NB-UVB 
phototherapy was added. No improvement was seen 
after 12 weeks of this combination treatment. 
Considering the failure of this combination rescue 
treatment, the patient initiated ixekizumab with the 
recommended induction and maintenance dose as 
per label. Notably, at week 4, the patient was almost 
completely cleared (absolute PASI<2; PASI 90 
response). Currently, after 24 weeks of treatment, the 
patient maintains an absolute PASI<2; PASI 90 
response, without any safety issues. 
 
Case Discussion 
We report a challenging case of a patient who did not 
respond to four different biologic agents (anti-TNF, 
anti-IL12/23, and anti-IL-17A). Switching to 
ixekizumab after failure to respond to secukinumab 
(including every other week maintenance dose) led 
to a remarkable clinical improvement, even though 
both agents are IL-17A inhibitors. This is in 
agreement with a recent report that showed that 
88.2 % of 17 secukinumab non-responder patients 
achieved PASI75 response at week 12 after switching 
to ixekizumab, regardless of the reason or timing of 
secukinumab discontinuation [1]. The reason for this 
is still unknown. 
Abstract 
 We report a patient with severe psoriasis who failed 
to respond to phototherapy, conventional systemic 
treatment and four biologic agents (etanercept, 
ustekinumab, adalimumab and secukinumab). 
Combination of a higher-dose secukinumab regimen 
with phototherapy had no success. Remarkably, 
ixekizumab, an IL-17A inhibitor, provided almost 
complete psoriasis clearance after 24 weeks of 
treatment. The reason for the success of ixekizumab 
after the failure to respond to a biologic with same 
mechanism of action is still unknown. Interestingly, 
failure of secukinumab does not preclude future 
therapeutic success with a second IL-17A-inhibitor. 
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Although ixekizumab and secukinumab share the 
same mechanism of action, it does not mean that 
they are equal or have the same clinical results. Small 
differences in the properties of an antibody, such as 
affinity, specificity, and solubility, may have a large 
impact in terms of efficacy. Hypothetical 
explanations for this distinct clinical outcome 
include a very high binding affinity of ixekizumab to 
human IL-17A (KD<3pM), compared to secukinumab 
(KD between 60 370 pM, average approximately 
200pM) [2, 3]. Additionally, the difference in the 
binding affinity to human IL-17A/F heterodimer may 
also have clinical impact, as ixekizumab binds to 
human IL-17A/F heterodimer with high affinity 
(KD<3pM) whereas secukinumab affinity is 
considerably lower (KD ~2000pM), [2, 3]. This seems 
important since IL-17A/F heterodimer and IL-17A 
homodimers signal through the same IL -17 receptor 
A/receptor C complex (IL-17RA/RC), [4]. Moreover, IL-
17A/F heterodimer is a two-faced cytokine closely 
mimicking IL- 17A as well as IL-17F [2 4]. 
Additionally, emerging evidence suggests that IL-
17F contributes to chronic tissue inflammation 
beyond IL-17A alone [5]. Dual neutralization of IL-
17A and IL-17F with a new monoclonal antibody 
bimekizumab showed greater suppression of in vitro 
cytokine responses and neutrophil chemotaxis than 
inhibition of IL-17A alone, also showing clinical 
efficacy in moderate to severe psoriasis and psoriatic 
arthritis [5, 6]. Albeit secukinumab and ixekizumab 
do not show significant interaction with human IL-
17F homodimer; there is a significant difference 
regarding their affinity to human IL-17A/F 
heterodimer. This difference may be another 
explanation for the efficacy of ixekizumab in 
secukinumab non-responder patients. 
Finally, another issue of interest will be drug survival 
for ixekizumab. Recent reports demonstrated that 
secukinumab had the lowest drug survival among all 
the biologics [7, 8]. Differences in binding affinity are 
also pointed out as potential explanations. 
Secukinumab has a high loading dose that can lead 
to a rapid and convincing response. However, over 
time, the maintenance dose may be too low, leading 
to relapse at some threshold [7]. Nevertheless, these 
results should be interpreted with caution, as many 
secukinumab patients had been previously treated 
with more than 3 biologic agents, comprising a 
group of patients particularly difficult to treat. The 
long-term follow-up of this patient will be helpful to 
clarify this issue. 
Owing to its high affinity to IL-17A and IL-17A/F, 
ixekizumab may be an interesting treatment option 
in difficult-to-treat patients that previously failed 
other biologic agents, including IL-17A inhibitors. 
 
References  
 
 
1. Georgakopoulos JR, Phung M, Ighani A, Yeung J. Efficacy and 
safety of switching to ixekizumab in secukinumab non-
responders with plaque psoriasis: a multicenter retrospective 
study of interleukin (IL)-17A antagonist therapies. J Am Acad 
Dermatol. 2018;79(1):155-157. [PMID: 29307635]. 
2. Liu L, Lu J, Allan BW, Tang Y, Tetreault J, et al. Generation and 
characterization of ixekizumab, a humanized monoclonal 
antibody that neutralizes interleukin-17A. J Inflamm Res. 
2016;9:39 50. [PMID: 27143947]. 
3. European Medicines Agency. Secukinumab Assessment Report. 
2014 http://www.ema.europa.eu/docs/en_GB/document_library 
/EPAR__Public_assessment_report/human/003729/WC5001831
31.pdf/. Accessed on January 28, 2018. 
4. Goepfert A, Lehmann S, Wirth E, Rondeau J-M. The human IL-
17A/F heterodimer: a two-faced cytokine with unique receptor 
recognition properties. Sci Rep. 2017;7(1):8906. [PMID: 28827714]. 
Glatt S, Baeten D, Baker T, Griffiths M, Ionescu L, et al. Dual IL-17A 
and IL-17F neutralisation by bimekizumab in psoriatic arthritis: 
evidence from preclinical experiments and a randomised 
placebo-controlled clinical trial that IL-17F contributes to human 
chronic tissue inflammation. Ann Rheum Dis. 2018;77(4):523-532. 
[PMID: 29275332]. 
5. Papp KA, Merola JF, Gottlieb AB, Griffiths CEM, Cross N, et al. Dual 
neutralization of both interleukin 17A and interleukin 17F with 
bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 
12-week randomized, double-blinded, placebo-controlled phase 
2b trial. J Am Acad Dermatol. 2018. [PMID: 29609013]. 
6. Egeberg A, Ottosen MB, Gniadecki R, Broesby-Olsen S, Dam TN, et 
al. Safety, efficacy and drug survival of biologics and biosimilars 
for moderate-to-severe plaque psoriasis. Br J Dermatol. 
2018;178(2):509 19. [PMID: 29094341]. 
7. van den Reek JMPA, van Vugt LJ, van Doorn MBA, van der Kraaij 
GE, de Kort WJA, et al. Initial Results of Secukinumab Drug Survival 
in Patients with Psoriasis: A Multicentre Daily Practice Cohort 
Study. Acta Derm Venereol. 2018. [PMID: 29405245]. 
 
